40.97
6.26 (18.02%)
| Penutupan Terdahulu | 34.71 |
| Buka | 34.94 |
| Jumlah Dagangan | 1,877,342 |
| Purata Dagangan (3B) | 532,757 |
| Modal Pasaran | 1,949,833,088 |
| Harga / Buku (P/B) | 3.84 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| EPS Cair (TTM) | -2.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.05% |
| Nisbah Semasa (MRQ) | 23.31 |
| Aliran Tunai Operasi (OCF TTM) | -66.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -42.10 M |
| Pulangan Atas Aset (ROA TTM) | -31.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -48.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | MBX Biosciences, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.90 |
|
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 3.12% |
| % Dimiliki oleh Institusi | 106.60% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nvp Associates, Llc | 31 Dec 2025 | 2,136,335 |
| Aaron Wealth Advisors Llc | 31 Mar 2026 | 1,168,176 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HOERTER STEVEN L. | 29.78 | - | 11,938 | 355,514 |
| Jumlah Keseluruhan Kuantiti Bersih | 11,938 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 355,514 | |||
| Purata Pembelian Keseluruhan ($) | 29.78 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HOERTER STEVEN L. | Pengarah | 01 May 2026 | Diperolehi (+) | 11,938 | 29.78 | 355,514 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |